Alvotech announced that its AVT80‑GL‑P01 pharmacokinetic study met all primary endpoints, demonstrating PK similarity to the reference Entyvio® (vedolizumab) in healthy adults. The single‑dose, double‑blind, parallel‑group trial also confirmed comparable safety, tolerability and immunogenicity profiles, giving the company a clear regulatory pathway for both the subcutaneous AVT80 and intravenous AVT16 formulations.
The successful study unlocks the next phase of regulatory submissions and positions Alvotech to launch a cost‑effective alternative to Entyvio®, a blockbuster drug that generated roughly $6.4 billion in global net revenues in 2025. By achieving PK equivalence, Alvotech can accelerate its approval process, potentially capturing a share of the ulcerative colitis and Crohn’s disease market and creating a new revenue stream for the company.
Joseph McClellan, Alvotech’s Chief Operating Officer, said, “We are very pleased with this result, which is an important milestone in the development of our proposed biosimilar to Entyvio. It allows us to proceed toward regulatory submissions and further underlines the strength of our platform approach to biosimilar development and manufacture, combining a well‑designed and executed clinical study with a high‑quality manufacturing process and strong analytical capabilities.”
Investors responded positively to the announcement, citing the milestone’s significance for regulatory progress and the potential to tap into a multi‑billion‑dollar market. The study’s success is viewed as a key driver of confidence in Alvotech’s biosimilar pipeline and its ability to deliver on its growth strategy.
Alvotech’s vertically integrated model—encompassing development, manufacturing and commercialization—has been a cornerstone of its success. The company has already advanced other biosimilar candidates, including AVT05 (Simponi®) and AVT04 (Stelara®), and is preparing a confirmatory patient study for AVT16. The regulatory pathway for biosimilars requires robust PK data, and the AVT80‑GL‑P01 results satisfy that requirement, reducing the risk profile for future approvals. While competition from other biosimilar entrants remains, Alvotech’s strong analytical capabilities and manufacturing expertise provide a competitive edge.
The company will now focus on compiling the regulatory dossier and engaging with the FDA to discuss next steps. A successful submission could lead to market entry within the next 12–18 months, depending on regulatory review timelines, and would add a new product line to Alvotech’s portfolio, enhancing its revenue diversification and reinforcing its position in the inflammatory bowel disease space.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.